Chinese vitamin C makers off the hook for U.S. antitrust violations

Oct 19, 2016
Following a dismissal by a U.S. appeals court of a $147 million price-fixing judgment, Chinese lawyers say that the my-government-made-me-do-it antitrust defense may not work next time for PRC companies

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
 

Last month, a three-judge panel of the U.S. Court of Appeals for the Second Circuit vacated a $147 million lower court verdict and freed a Chinese pharmaceutical maker from U.S. antitrust liability for price-fixing on the basis of international comity.

This premium content is reserved for
China Law & Practice Subscribers.

A Premium Subscription Provides:

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment

SUBSCRIBE NOW

Subscribe Now

For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected].